Fate Therapeutics (FATE) Other financing activities (2017 - 2024)
Fate Therapeutics (FATE) reported Other financing activities of -$558000.0 for Q2 2024, down 1000.0% on a YoY basis from $62000.0 in Q3 2023, and down 200.0% quarter-over-quarter from $558000.0 in Q1 2024.
Fate Therapeutics (FATE) Other financing activities (2017 - 2024) Analysis & Trends
Fate Therapeutics has reported Other financing activities for 4 years, with the latest figure at -$558000.0 in Q2 2024.
- For the quarter ending Q2 2024, Other financing activities fell 1000.0% year-over-year to -$558000.0; the trailing twelve-month figure through Mar 2025 stood at $62000.0 (down 90.3% YoY), and the FY2021 full-year result was $133000.0, changed N/A from the prior year.
- Other financing activities for Q2 2024 stood at -$558000.0, down from $558000.0 in the prior quarter.
- The five-year high for Other financing activities was $558000.0 in Q1 2024, with the low at -$558000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Fate Therapeutics | 250.86 Mn | 250.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -558,000.00 |
| Jun 30, 2024 | -558,000.00 |
| Mar 31, 2024 | 558,000.00 |
| Mar 31, 2024 | 558,000.00 |
| Jun 30, 2023 | 62,000.00 |
| Jun 30, 2023 | 62,000.00 |
| Jun 30, 2018 | 19,000.00 |
| Jun 30, 2018 | 19,000.00 |
| Mar 31, 2018 | 251,000.00 |
| Mar 31, 2018 | 251,000.00 |
| Sep 30, 2017 | -55,000.00 |
| Sep 30, 2017 | -55,000.00 |
| Mar 31, 2017 | 65,000.00 |
| Mar 31, 2017 | 65,000.00 |